160 related articles for article (PubMed ID: 37041565)
1. Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study.
Zhang T; Auer P; Dong J; Cutler C; Dezern AE; Gadalla SM; Deeg HJ; Nazha A; Carlson KS; Spellman S; Bolon YT; Saber W
J Hematol Oncol; 2023 Apr; 16(1):37. PubMed ID: 37041565
[TBL] [Abstract][Full Text] [Related]
2. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
[TBL] [Abstract][Full Text] [Related]
3. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.
Dong J; Buradagunta CS; Zhang T; Spellman S; Bolon YT; DeZern AE; Gadalla SM; Deeg HJ; Nazha A; Cutler C; Cheng C; Urrutia R; Auer P; Saber W
J Hematol Oncol; 2023 Mar; 16(1):21. PubMed ID: 36899395
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
[TBL] [Abstract][Full Text] [Related]
6. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
[TBL] [Abstract][Full Text] [Related]
7. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
[TBL] [Abstract][Full Text] [Related]
9. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
[TBL] [Abstract][Full Text] [Related]
10. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
11. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress on Role of Gene Mutations in Prognostic Evaluation of Patients with Myelodysplastic Syndrome after Stem-Cell Transplantation--Review].
Hu YM; Cui S; Ji LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1330-1333. PubMed ID: 31418402
[TBL] [Abstract][Full Text] [Related]
13. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
Kharfan-Dabaja MA; Komrokji RS; Zhang Q; Kumar A; Tsalatsanis A; Perkins J; Nishihori T; Field T; Al Ali N; Mishra A; Sallman D; Salem KZ; Zhang L; Moscinski L; Fernandez HF; Lancet J; List A; Anasetti C; Padron E
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):753-758. PubMed ID: 28687222
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
[TBL] [Abstract][Full Text] [Related]
15. Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM; Sallman DA
Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
Bejar R; Stevenson KE; Caughey B; Lindsley RC; Mar BG; Stojanov P; Getz G; Steensma DP; Ritz J; Soiffer R; Antin JH; Alyea E; Armand P; Ho V; Koreth J; Neuberg D; Cutler CS; Ebert BL
J Clin Oncol; 2014 Sep; 32(25):2691-8. PubMed ID: 25092778
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
18. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia.
Schwartz JR; Walsh MP; Ma J; Lamprecht T; Wang S; Wu G; Raimondi S; Triplett BM; Klco JM
Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 29891567
[TBL] [Abstract][Full Text] [Related]
19. Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.
Yu Y; Zhang T; Bao X; Wang Q; Zhang L; Hong Y; Zeng Z; Shen H; Wu D; Pan J; Liu H; Chen S; Sun A
Leuk Lymphoma; 2020 Apr; 61(4):919-926. PubMed ID: 31842651
[TBL] [Abstract][Full Text] [Related]
20. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
